前列地尔脂微球载体注射液治疗冠心病合并闭塞性周围动脉粥样硬化效果被引量：1

下载PDF

导出

摘要目的探讨前列地尔脂微球载体注射液(Lipo-PGE1)治疗冠心病(CHD)合并闭塞性周围动脉粥样硬化(PAOD)的效果。方法将96例CHD合并PAOD患者分为观察组和对照组,各48例。对照组给予常规抗血小板及调脂治疗,观察组在常规治疗的基础上加用Lipo-PGE1治疗。治疗前后,观察两组患者6min步行距离(6MWD)、踝肱指数(ABI)、心排量、代谢当量、同型半胱氨酸(Hcy)及超敏C反应蛋白(hs-CRP)水平,并统计两组不良反应发生情况。结果两组治疗前6MWD、ABI、心排量、代谢当量、Hcy及hs-CRP差异均无统计学意义(均P>0.05);治疗后,观察组6MWD、ABI、心排量及代谢当量均明显大于对照组(均P<0.05),而Hcy及hs-CRP水平则明显低于对照组(均P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论 Lipo-PGE1能明显改善CHD合并PAOD患者的ABI和运动耐量,有效降低Hcy及hs-CRP水平,是CHD合并PAOD安全有效的治疗方法。

作者李庆丰

机构地区平阳县人民医院

出处《现代实用医学》 2016年第6期782-783,797,共3页 Modern Practical Medicine

关键词冠状动脉疾病闭塞性前列地尔

分类号 R543.5 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Eo SR, Kwon C, Lee HJ, et al. Quantific- ation of the effect of Lipo-PGE1 on angi- ogenesis[J]. Journal of Plastic, Reconstruc- tive & Aesthetic Surgery, 2015, 68(1): 104-112.
2王静,彭永平,宫剑滨,蔡晓敏,刘挺松.前列地尔对冠心病合并糖尿病患者介入治疗后造影剂肾病的影响[J].东南国防医药,2014,16(1):28-30. 被引量：22
3Nishimura H, Enokida H, Tsuruta M, et al. Combination treatment using percu taneous transluminal angioplasty and low- density lipoprotein apheresis in a patient with peripheral arterial disease and a his- tory of chronic hemodialysis[J]. Journal of clinical apheresis, 2013, 28(4): 330-334.
4马东波.前列地尔(脂微球载体制剂)治疗糖尿病足疗效观察[J].河北医药,2013,35(1):100-101. 被引量：10
5Li J, Wang B, Wang Y, et al. Therapeutic effect of liposomal prostaglandin E1 in ac- ute lower limb ischemia as an adjuvant to hybrid procedures[J]. Experimental and therapeutic medicine, 2013, 5(6): 1760-1764.
6Sasaki Y, Suzuk! H, Itoh S, et al. K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models[J]. European journal of pharma- cology, 2012, 689(1): 132-138.
7刘倩倩,査滨,温亮,杨庆辉,陈延军.前列地尔脂微球载体注射液治疗冠心病并闭塞性周围动脉粥样硬化的疗效[J].心血管康复医学杂志,2012,21(2):168-172. 被引量：19
8Zhang N, Zhang Q, Chu T, et al. Formul-ation optimization of prostaglandin El- loaded lipid emulsion: Enhanced Stability and reduced biodegradation [J]. Pharma- ceutical development and technology, 2013, 18(4): 804-812.
9杨智勇,邵滢,果乃鹏.前列地尔脂微球载体对肾功能中度下降经皮冠状动脉介入治疗的肾脏保护作用[J].中日友好医院学报,2014,28(5):277-279. 被引量：7
10Kim MG, Jung YG, Eun YG. Effect of steroid, carbogen inhalation, and lipopro- staglandin E 1 combination therapy for sudden sensorineural heating loss[J]. Ameri- can journal of otolaryngology, 2011, 32 (2): 91-95.

二级参考文献46

1宋振强,王润秀.人重组表皮生长因子与碱性成纤维细胞生长因子联合应用对糖尿病创面愈合过程的修复效应[J].中国临床康复,2006,10(5):53-55. 被引量：22
2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量：98
3全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量：710
4Wu CC ,Wu CI,Wang WY,et al. Low concentrations of resveratrol poten- tiate the antiplatelet effect of Prostaglandins. Planta Medica, 2007,73: 439-443.
5Katzberg RW.Urography into the 21st century:new contrast media,renal handling,imaging characteristics,and nephrotoxi- city[J].Radiology, 1997,204 (2) : 297-312.
6Tumlin J,Stacul F,Adam A,et al.Pathophysiology of con- trast-induced nephropathy [J].Am J Cardiol,2006,98(6A): 14K-20K.
7Bartholomew BA,Haai KJ,Dukkipati S,et al.Impact of nephropathy after perqutaneous coronary intervention and a method for risk stratification[J].Am J Cardiol,2004,93(12): 1515-1519.
8Solomon R.The role of osmolality in the incidence of con-trast-induced nephrophathy:a systematic review of angio- graphic contrast media in high risk patients [J].Kidney Int, 2005,68 ( 12 ) : 2256.
9Muphy SW,Barrett BJ,Parfrey PS.Contrast nephropathy[J].J Am Soc Nephrol,2000,11 ( 1 ) : 177.
10Wu CC,Wu CI,Wang WY,et aLLow concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins [J].Planta Medica,2007,73:439-443.